Menu Search
Equities

Medicalgorithmics SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0QR8:LSE

Medicalgorithmics SA

Actions
  • Price (PLN)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta1.8244
Data delayed at least 20 minutes, as of Apr 09 2019.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Medicalgorithmics SA is a Poland-based company engaged in the advanced medical equipment and technology industry. The Company develops and manufactures system for the diagnosis of heart arrhythmia. Its product, named PocketECG, is used for remote monitoring of cardiac disorders, arrhythmia diagnosis and monitoring of heart, as well as is used for clinical drugs trials for cardiac safety. In addition, Medicalgorithmics SA provides services in the field of information technology and biotechnology, scientific research and development of natural sciences. Moreover, the Company works on the several projects, such as a device for tele-rehabilitation cardiology, software for optimizing repetitive task in hospitals, as well as devices and systems for remote description of the electrocardiography (ECG). It operates through MEDICALGORITHMICS US HOLDING CORPORATION and Medi-Lynx Cardiac Monitoring LLC and Medi-Lynx Cardiac Monitoring LLC.

  • Revenue in PLN (TTM)26.80m
  • Net income in PLN-15.38m
  • Incorporated2010
  • Employees117.00
  • Location
    Medicalgorithmics SAAl. Aleje Jerozolimskie 81Budynek Central Tower, 19. pietroWARSZAWA 02-001PolandPOL
  • Phone+48 228251249
  • Fax+48 228251249
  • Websitehttps://www.medicalgorithmics.pl/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.